Advertisement

Science China Life Sciences

, Volume 62, Issue 9, pp 1136–1137 | Cite as

Profile of Dr. Jia Fan

Profile From CAS & CAE Members
  • 5 Downloads

Selected Publications (2014–2019)

  1. Cai, J., Shi, G., Dong, Z., Ke, A., Ma, H., Gao, Q., Shen, Z., Huang, X., Chen, H., Yu, D., et al. (2015). Ubiquitin-specific protease 7 accelerates p14(ARF) degradation by deubiquitinating thyroid hormone receptor-interacting protein 12 and promotes hepatocellular carcinoma progression. Hepatology 61, 1603–1614.CrossRefGoogle Scholar
  2. Dong, L.Q, Shi, Y., Ma, L.J., Yang, L.X., Wang, X.Y., Zhang, S., Wang, Z.C., Duan, M., Zhang, Z., Liu, L.Z., et al. (2018). Spatial and temporal clonal evolution of intrahepatic cholangiocarcinoma. J Hepatol 69, 89–98.CrossRefGoogle Scholar
  3. Duan, M., Goswami, S., Shi, J., Wu, L., Wang, X., Ma, J., Zhang, Z., Shi, Y., Ma, L., Zhang, S., et al. (2019). Activated and exhausted MAIT cells foster disease progression and indicate poor outcome in hepatocellular carcinoma. Clin Cancer Res, 25, 3304–3316.CrossRefGoogle Scholar
  4. Duan, M., Hao, J., Cui, S., Worthley, D.L., Zhang, S., Wang, Z., Shi, J., Liu, L., Wang, X., Ke, A., et al. (2018). Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing. Cell Res 28, 359–373.CrossRefGoogle Scholar
  5. Duan, M., Wang, Z., Wang, X., Shi, J., Yang, L., Ding, Z., Gao, Q., Zhou, J., Fan, J. (2015). TREM-1, an inflammatory modulator, is expressed in hepatocellular carcinoma cells and significantly promotes tumor progression. Ann Surg Oncol 22, 3121–3129.CrossRefGoogle Scholar
  6. Gao, Q., Wang, Z., Duan, M., Lin, Y., Zhou, X., Worthley, D., Wang, X., Niu, G., Xia, Y., Deng, M., et al. (2017). Cell culture system for analysis of genetic heterogeneity within hepatocellular carcinomas and response to pharmacologic agents. Gastroenterology 152, 232–242.e4.CrossRefGoogle Scholar
  7. Gao, Q., Zhao, Y., Wang, X., Guo, W., Gao, S., Wei, L., Shi, J., Shi, G., Wang, Z., Zhang, Y., et al. (2014). Activating mutations in PTPN3 promote cholangiocarcinoma cell proliferation and migration and are associated with tumor recurrence in patients. Gastroenterology 146, 1397–1407.CrossRefGoogle Scholar
  8. Guo, W., Sun, Y., Shen, M., Ma, X., Wu, J., Zhang, C., Zhou, Y., Xu, Y., Hu, B., Zhang, M., et al. (2018). Circulating tumor cells with stem-like phenotypes for diagnosis, prognosis, and therapeutic response evaluation in hepatocellular carcinoma. Clin Cancer Res 24, 2203–2213.CrossRefGoogle Scholar
  9. Guo, W., Yang, X., Sun, Y., Shen, M., Ma, X., Wu, J., Zhang, C., Zhou, Y., Xu, Y., Hu, B., et al. (2014). Clinical significance of EpCAM mRNA-positive circulating tumor cells in hepatocellular carcinoma by an optimized negative enrichment and qRT-PCR-based platform. Clin Cancer Res 20, 4794–4805.CrossRefGoogle Scholar
  10. Hu, B., Yang, X., Xu, Y., Sun, Y., Sun, C., Guo, W., Zhang, X., Wang, W., Qiu, S., Zhou, J., et al. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clin Cancer Res 20, 6212–6222.Google Scholar
  11. Jiang, Y., Sun, A., Zhao, Y., Ying, W., Sun, H., Yang, X., Xing, B., Sun, W., Ren, L., Hu, B., et al. (2019). Chinese human proteome project C: Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature 567, 257–261.CrossRefGoogle Scholar
  12. Liu, L., Zhang, Z., Zheng, B., Shi, Y., Duan, M., Ma, L., Wang, Z., Dong, L., Dong, P., et al. (2019). CCL15 recruits suppressive monocytes to facilitate immune escape and disease progression in hepatocellular carcinoma. Hepatology 69, 143–159.CrossRefGoogle Scholar
  13. Sun, Y., Guo, W., Xu, Y., Shi, Y., Gong, Z., Ji, Y., Du, M., Zhang, X., Hu, B., Huang, A., et al. (2018). Circulating tumor cells from different vascular sites exhibit spatial heterogeneity in epithelial and mesenchymal composition and distinct clinical significance in hepatocellular carcinoma. Clin Cancer Res 24, 547–559.CrossRefGoogle Scholar
  14. Wang, Z., Gao, Q., Shi, J., Guo, W., Yang, L., Liu, X., Liu, L., Ma, L., Duan, M., Zhao, Y., et al. (2015). Protein tyrosine phosphatase receptor S acts as a metastatic suppressor in hepatocellular carcinoma by control of epithermal growth factor receptor-induced epithelial-mesenchymal transition. Hepatology 62, 1201–1214.CrossRefGoogle Scholar
  15. Wang, Z., Peng, Y., Hu, J., Wang, X., Sun, H., Sun, J., Shi, Y., Xiao, Y., Ding, Z., Yang, X., et al. (2018). Associating liver partition and portal vein ligation for staged hepatectomy for unresectable hepatitis B virus- related hepatocellular carcinoma: A single center study of 45 patients. Ann Surg, doi:  https://doi.org/10.1097/sla.0000000000002942 Google Scholar
  16. Yang, L., Gao, Q., Shi, J., Wang, Z., Zhang, Y., Gao, P., Wang, X., Shi, Y., Ke, A., Shi, G., et al. (2015). Mitogen-activated protein kinase kinase kinase 4 deficiency in intrahepatic cholangiocarcinoma leads to invasive growth and epithelial-mesenchymal transition. Hepatology 62, 1804–1816.CrossRefGoogle Scholar
  17. Ye, J., Li, T., Xu, G., Zhao, Y., Zhang, N., Fan, J., Wu, J. (2017). JCAD promotes progression of nonalcoholic steatohepatitis to liver cancer by inhibiting LATS2 kinase activity. Cancer Res 77, 5287–5300.CrossRefGoogle Scholar
  18. Yue, X., Ai, J., Xu, Y., Chen, Y., Huang, M., Yang, X., Hu, B., Zhang, H., He, C., Yang, X., et al. (2017). Polymeric immunoglobulin receptor promotes tumor growth in hepatocellular carcinoma. Hepatology 65, 1948–1962.CrossRefGoogle Scholar

Copyright information

© Science China Press and Springer-Verlag GmbH Germany, part of Springer Nature 2019

Personalised recommendations